Tirucherai, Giridhar S.

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity

Fibroblast Growth Factor ResearchLiver Disease Diagnosis and Treatment

Cited by 257

BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial

Lawitz, E. J., Shevell, D. E., Tirucherai, G. S., Du, S., Chen, W., Kavita, U., Coste, A., Poordad, F., Karsdal, M., Nielsen, M., et al. (2022) · Hepatology

Liver physiology and pathologyHepatitis C virus research

Cited by 107

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry

Sphingolipid Metabolism and SignalingInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 61

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 59

BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study

Tirucherai, G., Yu, D., Revankar, R., Klinger, G., Van Lier, J. J., Taubel, J., & Correll, T. (2019) · Rare ILD/DPLD

Sphingolipid Metabolism and SignalingInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 6